Biotechnology involves using living organisms and biological systems to develop useful products and processes. India is now among the world’s top 12 biotechnology hubs.
Activity in the field of Biotechnology in India
Robust Government Policy: Initiatives like the National Biotechnology Development Strategy 2021-2025 have provided a roadmap for a $150 billion bio-economy by 2025.
Institutional Framework: The Department of Biotechnology (DBT) and BIRAC provide critical seed funding and mentorship to over 5,000 startups.
Cost-Effective R&D: India offers a significant cost advantage (nearly 33% lower) in R&D and manufacturing compared to developed nations, attracting Global Capability Centers (GCCs).
Vast Biodiversity and Genetic Pool: India’s diverse climatic zones and ethnic genetic diversity provide a massive “natural laboratory” for genomic research and agricultural biotech.
Human Capital: A steady influx of STEM graduates (over 2 million annually) provides the technical workforce required for high-end lab work and clinical trials.
Infrastructure Growth: The establishment of specialized Biotech Parks offers “plug-and-play” facilities for rapid scaling. Eg- Genome Valley in Hyderabad.
FDI Liberalization: 100% Foreign Direct Investment (FDI) is permitted under the automatic route for greenfield projects, boosting capital infusion.
Digital Integration: The use of AI and Big Data in bioinformatics, supported by the National Supercomputing Mission has accelerated drug discovery and protein folding research.
Pandemic Legacy: The successful indigenous development of vaccines (e.g., Covaxin) proved India’s “Proof of Concept” to the world, triggering massive reinvestment in the sector.
Activity benefitting the field of Biopharma
Global Vaccine Leadership: India now supplies approximately 60% of the world’s vaccines, earning the title Pharmacy of the World.
Increase Economical Value: The Indian bioeconomy reached an estimated $130-$165.7 billion in 2024, with projections to reach $300 billion by 2030.
Shift to Biosimilars: Biotechnology has enabled India to move beyond simple generics to complex Biosimilars. India has the highest number of biosimilars approved globally.
Precision Medicine: Allowed biopharma companies to develop targeted therapies for cancer and rare genetic disorders tailored to the Indian populations
Clinical Trial Hub: Improved regulatory frameworks such as New Drugs and Clinical Trial Rules, 2019 and biotech expertise have made India a preferred destination for multi-centric global clinical trials.
Reduced Import Dependency: Local production of Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) through fermentation technology is reducing reliance on imports.
Innovation in Biologics: Companies like Zydus Cadila and Dr. Reddy’s are now shifting from “imitative” to “innovative” R&D, focusing on novel biologics for autoimmune diseases.
Diagnostics Revolution: The biotech boom led to the rapid development of low-cost, molecular diagnostic kits such as RT-PCR, CRISPR-based ‘Feluda’ tests, improving healthcare penetration.
Major challenges
High Capital Intensity: Developing a single biosimilar costs $100-250 million, deterring smaller Indian firms from competing.
Complex Manufacturing Requirements: Biologics require ultra-pure environments, even a 1°C temperature shift can spoil entire production batches.
Innovation Deficit: India still invests only 7-8% of revenue in R&D compared to 20%+ by global innovators.
Skill Gap in Advanced Tech: Shortage of professionals trained in bioinformatics, transcriptomics, and computational biology slows down innovation.
Global Intellectual Property (IP) Conflicts: Navigating the “patent thickets” of global biopharma giants remains a major legal challenge for biosimilars.
Infrastructure Deficit in NAMs: Lack of standardized, industry-ready laboratories for non-animal methodologies across the country.
Supply Chain Fragility: India remains dependent on imported raw materials like specialized cell culture media for biotech production.
Way forward
Strengthening Regulatory Cadre: Creating a dedicated “Scientific Review Cadre” within CDSCO to match global approval timelines.
Expanding Clinical Trial Capacity: Establishing a national network of 1,000 accredited clinical trial sites to accelerate drug development.
Investing in Biofoundries under BioE3 Policy to provide common infrastructure for startups to test and scale.
Academic-Industry Collaboration: Upgrading seven NIPERs into “Centers of Excellence” for translational research and high-end skilling.
Strategic Use of Free Trade Agreements: Leveraging FTAs with the EU and UK to harmonize quality standards and boost exports.
By bridging the gap between laboratory research and commercial biopharma, India is moving toward Atmanirbhar Bharat in healthcare.